Induction treatment outcome for nonprioritized cytogenetic groups
| Cytogenetic group . | No. of patients . | No. of CRs (%) . | P4-150 . | Early death4-151(%) . | Resistant disease‡ (%) . |
|---|---|---|---|---|---|
| Normal | 582 | 395 (68) | 66 (11) | 121 (21) | |
| del(9q) | 33 | 31 (94) | .001 | 0 (0) | 2 (6) |
| Sole del(9q) | 11 | 10 (91) | .19 | 0 (0) | 1 (9) |
| t(8;21) | 81 | 74 (91) | <.001 | 2 (2) | 5 (6) |
| inv(16) or t(16;16) | 96 | 82 (85) | <.001 | 10 (10) | 4 (4) |
| −X | 18 | 15 (83) | .20 | 1 (6) | 2 (11) |
| Balanced abn(11q23) | 54 | 40 (74) | .37 | 7 (13) | 7 (13) |
| t(9;11) | 27 | 23 (85) | .09 | 3 (11) | 1 (4) |
| t(11;v)4-153 | 13 | 9 (69) | 1.00 | 1 (8) | 3 (23) |
| t(6;11) | 8 | 5 (63) | .72 | 3 (38) | 0 (0) |
| t(11;19)(q23;p13.1) | 6 | 3 (50) | .39 | 0 (0) | 3 (5) |
| del(13q) | 9 | 6 (67) | 1.00 | 0 (0) | 3 (33) |
| −Y | 58 | 38 (66) | .77 | 8 (14) | 12 (21) |
| Sole −Y | 14 | 10 (71) | 1.00 | 4 (29) | 0 (0) |
| +22 | 31 | 20 (65) | .84 | 4 (13) | 7 (23) |
| +8 | 123 | 71 (58) | .04 | 24 (20) | 28 (23) |
| +21 | 28 | 16 (57) | .30 | 2 (7) | 10 (36) |
| +13 | 29 | 16 (55) | .16 | 6 (21) | 7 (24) |
| del(11q) | 12 | 6 (50) | .22 | 3 (25) | 3 (25) |
| +4 | 14 | 7 (50) | .25 | 5 (36) | 2 (14) |
| +11 | 20 | 9 (45) | .05 | 4 (20) | 7 (35) |
| +14 | 12 | 5 (42) | .07 | 3 (25) | 4 (33) |
| −7/7q− | 95 | 41 (43) | <.001 | 14 (15) | 40 (42) |
| −7 | 47 | 20 (43) | <.001 | 5 (11) | 22 (47) |
| Loss of 7q | 29 | 10 (34) | <.001 | 5 (17) | 14 (48) |
| del(7q) | 19 | 11 (58) | .46 | 4 (21) | 4 (21) |
| −20/20q− | 39 | 15 (38) | <.001 | 8 (21) | 16 (41) |
| del(20q) | 16 | 8 (50) | .17 | 1 (6) | 7 (44) |
| −20 | 15 | 5 (33) | .007 | 4 (27) | 6 (40) |
| Loss of 20q | 8 | 2 (25) | .02 | 3 (38) | 3 (38) |
| t(6;9) | 8 | 3 (38) | .12 | 1 (13) | 4 (50) |
| abn(12p) | 33 | 11 (33) | <.001 | 9 (27) | 13 (39) |
| Unbalanced abn(12p) | 25 | 9 (36) | .001 | 7 (28) | 9 (36) |
| Balanced abn(12p) | 8 | 2 (25) | .02 | 2 (25) | 4 (50) |
| −5/5q− | 86 | 27 (31) | <.001 | 22 (26) | 37 (43) |
| del(5q) | 42 | 11 (26) | <.001 | 9 (21) | 22 (52) |
| −5 | 26 | 12 (46) | .03 | 8 (31) | 6 (23) |
| Loss of 5q | 18 | 4 (22) | <.001 | 5 (28) | 9 (50) |
| −17/17p− | 62 | 19 (31) | <.001 | 17 (27) | 26 (42) |
| −17 | 32 | 9 (28) | <.001 | 11 (34) | 12 (38) |
| Loss of 17p | 30 | 10 (33) | .001 | 6 (20) | 14 (47) |
| −18 | 30 | 8 (27) | <.001 | 8 (27) | 14 (47) |
| inv(3) or t(3;3) | 12 | 2 (17) | <.001 | 3 (25) | 7 (58) |
| Cytogenetic group . | No. of patients . | No. of CRs (%) . | P4-150 . | Early death4-151(%) . | Resistant disease‡ (%) . |
|---|---|---|---|---|---|
| Normal | 582 | 395 (68) | 66 (11) | 121 (21) | |
| del(9q) | 33 | 31 (94) | .001 | 0 (0) | 2 (6) |
| Sole del(9q) | 11 | 10 (91) | .19 | 0 (0) | 1 (9) |
| t(8;21) | 81 | 74 (91) | <.001 | 2 (2) | 5 (6) |
| inv(16) or t(16;16) | 96 | 82 (85) | <.001 | 10 (10) | 4 (4) |
| −X | 18 | 15 (83) | .20 | 1 (6) | 2 (11) |
| Balanced abn(11q23) | 54 | 40 (74) | .37 | 7 (13) | 7 (13) |
| t(9;11) | 27 | 23 (85) | .09 | 3 (11) | 1 (4) |
| t(11;v)4-153 | 13 | 9 (69) | 1.00 | 1 (8) | 3 (23) |
| t(6;11) | 8 | 5 (63) | .72 | 3 (38) | 0 (0) |
| t(11;19)(q23;p13.1) | 6 | 3 (50) | .39 | 0 (0) | 3 (5) |
| del(13q) | 9 | 6 (67) | 1.00 | 0 (0) | 3 (33) |
| −Y | 58 | 38 (66) | .77 | 8 (14) | 12 (21) |
| Sole −Y | 14 | 10 (71) | 1.00 | 4 (29) | 0 (0) |
| +22 | 31 | 20 (65) | .84 | 4 (13) | 7 (23) |
| +8 | 123 | 71 (58) | .04 | 24 (20) | 28 (23) |
| +21 | 28 | 16 (57) | .30 | 2 (7) | 10 (36) |
| +13 | 29 | 16 (55) | .16 | 6 (21) | 7 (24) |
| del(11q) | 12 | 6 (50) | .22 | 3 (25) | 3 (25) |
| +4 | 14 | 7 (50) | .25 | 5 (36) | 2 (14) |
| +11 | 20 | 9 (45) | .05 | 4 (20) | 7 (35) |
| +14 | 12 | 5 (42) | .07 | 3 (25) | 4 (33) |
| −7/7q− | 95 | 41 (43) | <.001 | 14 (15) | 40 (42) |
| −7 | 47 | 20 (43) | <.001 | 5 (11) | 22 (47) |
| Loss of 7q | 29 | 10 (34) | <.001 | 5 (17) | 14 (48) |
| del(7q) | 19 | 11 (58) | .46 | 4 (21) | 4 (21) |
| −20/20q− | 39 | 15 (38) | <.001 | 8 (21) | 16 (41) |
| del(20q) | 16 | 8 (50) | .17 | 1 (6) | 7 (44) |
| −20 | 15 | 5 (33) | .007 | 4 (27) | 6 (40) |
| Loss of 20q | 8 | 2 (25) | .02 | 3 (38) | 3 (38) |
| t(6;9) | 8 | 3 (38) | .12 | 1 (13) | 4 (50) |
| abn(12p) | 33 | 11 (33) | <.001 | 9 (27) | 13 (39) |
| Unbalanced abn(12p) | 25 | 9 (36) | .001 | 7 (28) | 9 (36) |
| Balanced abn(12p) | 8 | 2 (25) | .02 | 2 (25) | 4 (50) |
| −5/5q− | 86 | 27 (31) | <.001 | 22 (26) | 37 (43) |
| del(5q) | 42 | 11 (26) | <.001 | 9 (21) | 22 (52) |
| −5 | 26 | 12 (46) | .03 | 8 (31) | 6 (23) |
| Loss of 5q | 18 | 4 (22) | <.001 | 5 (28) | 9 (50) |
| −17/17p− | 62 | 19 (31) | <.001 | 17 (27) | 26 (42) |
| −17 | 32 | 9 (28) | <.001 | 11 (34) | 12 (38) |
| Loss of 17p | 30 | 10 (33) | .001 | 6 (20) | 14 (47) |
| −18 | 30 | 8 (27) | <.001 | 8 (27) | 14 (47) |
| inv(3) or t(3;3) | 12 | 2 (17) | <.001 | 3 (25) | 7 (58) |
CR indicates complete remission.
For comparison of a given abnormality with normal cytogenetics.
Death within 30 days of initiating induction.
Survival beyond 30 days without attaining CR.
v denotes various chromosomes (other than chromosomes 6, 9, and 19 with a break at p13.1) participating in translocations with chromosome 11 at band q23.